Skip to Main Navigation
Skip to Page Content
COVID-19 is an emerging, rapidly evolving situation.

Get the latest public health information from CDC and research information from NIH.

U.S. flag

An official website of the United States government

Dot gov

The .gov means it's official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Share This:
https://ntp.niehs.nih.gov/go/10975

Target Organs and Levels of Evidence for TR-435

Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6-t-butyl-m-cresol) (CASRN 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies)

Chemical (Study Title)
CASRN		 Peer Review Date Route/Exposure Levels Study Laboratory
4,4-Thiobis(6-tert-butyl-m-cresol)
96-69-5		 06/22/1993 Dosed-Feed
R: 0,.05,.1,.25, M: 0,.025,.05,.1 %		 Battelle Columbus Laboratory

Levels of Evidence

Male Rats: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • LIVER: KUPFFER CELL HYPERTROPHY; CYTOPLASMIC VACUOLIZATION; MIXED CELL FOCI
Female Rats: No Evidence
Type Organ/Tissue (Lesion)
Non-Neoplastic Lesions
  • LIVER: KUPFFER CELL HYPERTROPHY; CYTOPLASMIC VACUOLIZATION; FATTY CHANGE; MIXED CELL FOCI
  • KIDNEY: INCREASED SEVERITY OF NEPHROPATHY
Other Considerations
  • MAMMARY GLAND: FIBROADENOMA, ADENOMA, OR CARCINOMA COMBINED 32/50 24/50 11/50 16/50
Male Mice: No Evidence
Type Organ/Tissue (Lesion)
Other Considerations
  • LIVER: FATTY CHANGE 19/50 17/50 5/50 6/50; CLEAR CELL FOCI 6/50 5/50 2/50 0/50; ADENOMA OR CARCINOMA COMBINED 25/50 30/50 27/50 16/50
Female Mice: No Evidence